Trial Profile
The Efficacy and Safety of Apatinib Plus Etoposide as the Maintence Trerapy in Extensive-stage Small-cell Lung Cancer After Second-line Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2017
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Oct 2017 New trial record